Verition Fund Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,932,153
| Closed | -$8.12M | – | 2741 |
|
|
2023
Q1 | $8.12M | Buy |
1,932,153
+476,564
| +33% | +$2.47M | 0.11% | 238 |
|
|
2022
Q4 | $8.75M | Buy |
1,455,589
+214,278
| +17% | +$1.17M | 0.14% | 185 |
|
|
2022
Q3 | $7.22M | Sell |
1,241,311
-43,014
| -3% | -$268K | 0.08% | 283 |
|
|
2022
Q2 | $7.67M | Buy |
1,284,325
+289,045
| +29% | +$1.48M | 0.15% | 157 |
|
|
2022
Q1 | $4.65M | Sell |
995,280
-150,000
| -13% | -$447K | 0.06% | 423 |
|
|
2021
Q4 | $2.84M | Buy |
1,145,280
+9,231
| +0.8% | +$22.6K | 0.02% | 666 |
|
|
2021
Q3 | $3.35M | Buy |
1,136,049
+157,370
| +16% | +$429K | 0.03% | 392 |
|
|
2021
Q2 | $2.45M | Sell |
978,679
-133,001
| -12% | -$319K | 0.02% | 453 |
|
|
2021
Q1 | $3.23M | Buy |
1,111,680
+122,078
| +12% | +$399K | 0.04% | 289 |
|
|
2020
Q4 | $3.19M | Buy |
989,602
+218,871
| +28% | +$728K | 0.03% | 280 |
|
|
2020
Q3 | $1.66M | Buy |
+770,731
| New | +$984K | 0.03% | 284 |
|
|
2018
Q2 | – | Sell |
-11,233
| Closed | -$44K | – | 1485 |
|
|
2018
Q1 | $44K | Buy |
+11,233
| New | +$39.5K | ﹤0.01% | 1084 |
|
|
2015
Q3 | – | Sell |
-2,061
| Closed | -$40K | – | 884 |
|
|
2015
Q2 | $40K | Buy |
+2,061
| New | +$39.8K | 0.01% | 593 |
|
|
2014
Q3 | – | Sell |
-2,583
| Closed | -$73K | – | 1006 |
|
|
2014
Q2 | $73K | Buy |
+2,583
| New | +$77.6K | 0.01% | 619 |
|
Other funds holding CTIC
Verition Fund Management's CTIC Position: Q2 2023 in Review
Verition Fund Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,932,153 shares — an estimated $8.12M sold.
Verition Fund Management first reported a position in CTIC in Q2 2014 and held it in 14 quarters. The position peaked at $8.75M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Verition Fund Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Verition Fund Management sold 1,932,153 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $8.12M.
- Verition Fund Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2014 and held it in 14 quarters.
- Verition Fund Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.75M in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Verition Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.